Cellular Autotransplantation for Ischemic and Idiopathic Dilated Cardiomyopathy. Preliminary Report

Argüero, R; Careaga-Reyna, Guillermo; Castaño-Guerra, Rodolfo; Garrido-Garduño, Martín H.; Magaña-Serrano, José Antonio; Nambo-Lucio, María de Jesús

doi:10.1016/j.arcmed.2006.05.012

Cited by 23 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No adverse events have been reported in a trial where mononuclear cells were delivered to the coronary arteries in 24 patients after coronary sinus occlusion (19). Another trial used the intramyocardial route to deliver cells during thoracotomy, but only 5 IDC patients were included in the trial that reported 7 episodes of ventricular fibrillation during the procedure and 2 deaths by the same mechanism during the perioperative period (18). A third trial was interrupted for safety reasons after performing mononuclear cell injection by catheterization with balloon inflation in two patients (20).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A safety and feasibility study of cell therapy in dilated cardiomyopathy

Martino

Oliveira

Souza

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Very few studies have applied cell therapy to patients with non-ischemic dilated cardiomyopathy (18)(19)(20)(21), and conflicting results as to the safety of the procedure have been reported.…”

mentioning

confidence: 99%

A safety and feasibility study of cell therapy in dilated cardiomyopathy

Martino

Oliveira

Souza

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

“…One study reported APC transplant in 39 cardiomyopathy subjects including 5 with nonischemic cardiomyopathy. Of note, 7 of 39 developed ventricular fibrillation during thoracotomy and open intramyocardial injection similar to the procedure used in this patient [7]. Of the seven subjects with arrhythmias, two developed intractable, lethal ventricular tachyarrhythmias, although the findings do not distinguish between the type of underlying cardiomyopathy.…”

Section: Discussionmentioning

confidence: 93%

Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy

Pytel

Husain

Moskowitz

et al. 2010

Cardiovascular Pathology

View full text Add to dashboard Cite

A 41 year old male with cardiomyopathy from an inherited β myosin heavy chain mutation underwent treatment for heart failure with intramyocardial cell transplantation. He received direct injections into his heart of autologous precursor cells isolated from his blood. He immediately suffered ventricular fibrillation. Although he was resuscitated, he experienced a prolonged downward course that prohibited his undergoing transplantation. His autopsy revealed marked fibrosis throughout the myocardium with areas of mononuclear cell infiltrate. This case highlights the potential adverse effects associated with intramyocardial therapy in the cardiomyopathic heart. Keywords hypertrophic cardiomyopathy; intramyocardial cell therapy; stem cells; transplant Clinical CourseThe patient was a 41 year old male with a family history of sudden death who was diagnosed with hypertrophic cardiomyopathy (HCM) at the age of 9; he remained active and without symptoms throughout his young adult life. Genetic testing revealed a heterozygous mutation in exon 19 of MYH7, the gene encoding β myosin heavy chain. This mutation, 2146g>a, results in the pathogenic change G716 to R716. He had a syncopal episode at age 35 for which he received an internal cardioverter defibrillator (ICD). At age 35, he developed paroxysmal atrial fibrillation. He subsequently developed dilated cardiomyopathy with progressive congestive heart failure despite therapy with angiotensin converting enzyme inhibitor, beta blockade and diuretics. He had an ablation for atrial flutter. Because of advanced heart failure, he was

show abstract

“…Published reports of completed clinical trials indicate MSCs may improve cardiac function after stroke or myopathy. 1,8,9,22,26,27,31 To support translational research efforts, recent in vitro studies have investigated several avenues by which MSCs may contribute to a potential therapy including: paracrine effects on resident cells and recruitment of additional cells, 13,17,21,23,28,32 local matrix remodeling, 35 and differentiation of the MSCs themselves along vascular smooth muscle-like 2, 16,31,42 or endothelial-like 29,31,43 lineages. These previous and ongoing efforts signify growing interest from the clinical, translational, and basic science research communities in determining the potential of MSCs to contribute to cardiovascular therapies.…”

Section: Introductionmentioning

confidence: 99%

Human Mesenchymal Stem Cells Form Multicellular Structures in Response to Applied Cyclic Strain

2009

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are a component of many cardiovascular cell-based regenerative medicine therapies. There is little understanding, however, of the response of MSCs to mechanical cues present in cardiovascular tissues. The objectives of these studies were to identify a model system to study the effect of well-defined applied cyclic strain on MSCs and to use this system to determine the effect of cyclic equibiaxial strain on the cellular and cytoskeletal organization of MSCs. When exposed to 10%, 1 Hz cyclic equibiaxial strain for 48 h, MSCs remained viable, retained characteristic gene and protein markers, and rearranged to form multicellular structures defined as clusters and knobs. This novel observation of cluster (overlapping cells surrounded by radial cellular projections) and knob (more dome-like structure containing significantly more cells than a cluster) formation did not involve changes in cytoskeletal proteins and resulted from cellular rearrangements initiated within 8 h of applied strain. Observed cellular responses were found to be dependent on substrate coating, but not on cell density for the 8-fold ranges tested. This system can thus be used to study the mechanoresponse over hours to days of MSCs exposed to applied cyclic strain in the context of cell-cell and cell-matrix interactions.

show abstract

Cellular Autotransplantation for Ischemic and Idiopathic Dilated Cardiomyopathy. Preliminary Report

Cited by 23 publications

References 8 publications

A safety and feasibility study of cell therapy in dilated cardiomyopathy

A safety and feasibility study of cell therapy in dilated cardiomyopathy

Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy

Human Mesenchymal Stem Cells Form Multicellular Structures in Response to Applied Cyclic Strain

Contact Info

Product

Resources

About